Figure S6 from Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy

2026 Open access

Read full text
Authors: Gracia Gracia, Enyuan Cao, Daniel Yuen, Vilena D.M. Ferreira, Moore Z. Chen, Danielle Senyschyn, Justine D. Mintern, Angus P. R. Johnston, David W. Kang, Orlagh M. Feeney, Christopher J.H. Porter
DOI: 10.1158/2326-6066.31484150
Cited by: 0

Abstract

SC administration with PH20 maintains anti-tumour efficacy of αCTLA4 at lower αCTLA4 doses relative to SC alone or IV administration in CT26/HAS tumour mice.

Fields of Study & Subjects

Proteoglycans and glycosaminoglycans research Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses

Publication details

Publication date
4 March 2026
Language
EN